Prestige BioPharma프레스티지바이오파마
950210 · KOSPI · ₩950210 · 프레스티지바이오파마
- Market cap
- ₩303B
- Enterprise value
- ₩303B
- P/E
- 19,088.0×
- P/B
- 1,001.6×
- Dividend yield
- 0.0%
- ROE
- 5.2%
- Net margin
- 155.6%
Trailing 12 months from filed financial statements, as of FY 2025. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−64.2% from the high
₩4,940Today: ₩4,940 – ₩5,160₩14,120
Returns
- 1W−7.8%
- 1M−15.4%
- 3M−9.0%
- 6M−44.3%
- YTD−60.7%
- 1Y−61.8%
- Volume today
- 72,182
- 2.4× the 20-day average
- Traded today
- ₩362M
- Listed shares
- 60,096,155
- EPS (12 months)
- ₩0
- Earnings yield 0.0%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 54: heavy trading.
- MomentumWeak-13.8% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Prestige BioPharma stock overview
Prestige BioPharma (프레스티지바이오파마, KRX: 950210) is listed on KOSPI, in the Biotech & Pharma sector. The company is a global biopharmaceutical firm focused on research, development and commercialization of antibody new drugs and biosimilars. Its shares closed at ₩5,050 on Oct 27, 2026, down 0.20% on the day, giving it a market value of ₩303B.
Key facts
- Market cap
- ₩303B
- Sector
- Biotech & Pharma
- Latest price change
- −0.20%
- As of
- Oct 27, 2026
- Main business
- The company is a global biopharmaceutical firm focused on research, development and commercialization of antibody new drugs and biosimilars.
Quick answers about Prestige BioPharma
- What does Prestige BioPharma do?
- The company is a global biopharmaceutical firm focused on research, development and commercialization of antibody new drugs and biosimilars. It develops innovative drugs mainly in cancer and hard-to-treat diseases, and sells biosimilars such as TUZNUE (a trastuzumab biosimilar) through regional partners in markets including the European Union, with additional export registrations pursued in Latin America, the Middle East and North Africa, and Southeast Asia. Its contract manufacturing (CDMO) services, carried out largely through its subsidiary Prestige BioLogics, support production for clients.
- What is the market cap of Prestige BioPharma?
- The market capitalisation of Prestige BioPharma was ₩303B at the close on Oct 27, 2026.
- Who are the largest shareholders of Prestige BioPharma?
- According to the latest official filings, the largest reported holders are Mason Partners (52.50%, as of Sep 1, 2026); Octavia Fund Limited (18.17%, as of Feb 13, 2025); Park So-yeon (15.76%, as of Aug 11, 2026).
- When is the next earnings report from Prestige BioPharma?
- Korean companies rarely announce results dates in advance. Based on when Prestige BioPharma filed the same report in past years, its next 3q results is expected between Nov 28, 2026 and Nov 29, 2026.
- Does the National Pension Service own Prestige BioPharma?
- Yes. The National Pension Service held 0.15% of Prestige BioPharma shares as of Dec 31, 2021.
Company profile
The company is a global biopharmaceutical firm focused on research, development and commercialization of antibody new drugs and biosimilars. It develops innovative drugs mainly in cancer and hard-to-treat diseases, and sells biosimilars such as TUZNUE (a trastuzumab biosimilar) through regional partners in markets including the European Union, with additional export registrations pursued in Latin America, the Middle East and North Africa, and Southeast Asia. Its contract manufacturing (CDMO) services, carried out largely through its subsidiary Prestige BioLogics, support production for clients.
Written by AI from the company's latest annual report.
- Korean name
- 프레스티지바이오파마
- Sector
- Biotech & Pharma
- CEO
- 박소연
- Founded
- Jul 2015
- Listed
- Feb 2021
- Listed shares
- 60,096,155
- Fiscal year ends
- Month 06
- Website
- www.prestigebiopharma.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Application for Appointment, Dismissal, or Change of External Auditor of Foreign Corporation Listed on KOSPISep 29, 2026
- Annual general meeting resultsSep 29, 2026
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent DirectorsSep 29, 2026
- Amended: Annual report (Jun 2026)Sep 23, 2026
- Annual report (Jun 2026)Sep 22, 2026
Titles in Korean until English translations are added.
Also known as: Prestige BioPharma / 프레스티지바이오파마 / 950210 / KRX:950210
Source: KRX statistical information